Skip to main
DOCS

Doximity (DOCS) Stock Forecast & Price Target

Doximity (DOCS) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 24%
Buy 24%
Hold 43%
Sell 10%
Strong Sell 0%

Bulls say

Doximity is a digital platform focused on providing healthcare professionals with tools for collaboration, staying up-to-date on medical news and research, managing careers and on-call schedules, and conducting virtual patient visits. The company has seen strong demand and customer engagement for its Marketing and Hiring Solutions, driven by an expanding AI commercial pipeline. The recent appointment of a new CFO and President brings additional expertise to the company. However, limited visibility into pharmaceutical budgets and increased competition could pose risks to future growth and profitability.

Bears say

Doximity is facing challenges in its core marketing solutions segment due to declining demand for pharmaceuticals and reductions in patent protection, causing lower marketing spends from pharmaceutical companies. Additionally, the company is facing increased competition in the AI market, which could impact its ability to grow above industry market growth. This, coupled with increased investment in AI and brand marketing, is expected to result in lower margins in the near term. Overall, these challenges are likely to impact the company's growth and profitability in the short term, leading to a negative outlook for its stock.

Doximity (DOCS) has been analyzed by 21 analysts, with a consensus rating of Buy. 24% of analysts recommend a Strong Buy, 24% recommend Buy, 43% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Doximity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Doximity (DOCS) Forecast

Analysts have given Doximity (DOCS) a Buy based on their latest research and market trends.

According to 21 analysts, Doximity (DOCS) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Doximity (DOCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.